News and Events
Discover our news and events, and information about our project.
January 31st, 2024
Lymphatica awarded FDA Breakthrough Device Designation
Lymphatica Medtech SA is awarded the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its revolutionary product, LymphoDrain. This breakthrough designation represents a significant milestone in the journey toward transforming the treatment landscape for chronic lymphedema.
October 12-14, 2023
Lymphatica is at the European Society of Vascular Medicine
Prof. Lucia Mazzolai is presenting the LymphoPilot clinical study at the Congress of the European Society of Vascular Medicine (Milan, October 12-14), in a plenary session from the title: “Novelties in lymphedema treatment”
Lymphatica Medtech has a booth: come to visit us!
September 18th - 22nd, 2023
LSI Europe 2023 - Emerging Medtech Summit
Our CEO Marco Pisano will be present in Barcelona at the LSI 2023 – Emerging Medtech Summit.
If you are interested in Lymphatica investment opportunity, please contact him for a meeting.
September 11th - 14th, 2023
Lymphatica is at the ILS 2023 - 29th World Congress of Lymphology
Lymphatica is present at this world-class event at Booth number 10 – come visit us!
Moreover, the Angiology group from CHUV will present our pilot clinical study on October 14 at 11:45 in the Libeccio Hall.
June 27th, 2023
John Erb joins the Board of Director & Nanci Govinder is elected Chairperson
Nanci Govinder, already board member of Lymphatica since 2018, kindly accepted to step-up as Chairperson of the Board. Her extensive experience will be instrumental to ensure the Company focus on strategic matters and to set high governance standards.
Moreover, we welcome John Erb as new Board Member. Previously Chairman of Vascular Solutions Inc. (acquired by Teleflex) and Board Member of CryoCath Technologies (acquired by Medtronic) and of Senox Inc. (acquired by CR Bard), and currently Chairman of Nuwellis, Inc – a global medical device company listed on Nasdaq focused on heart failure products – Mr. John Erb brings a wealth of experience in developing and marketing vascular products internationally.
June 22nd - 24th, 2023
Lymphatica is at the 16th Congress of the International Society of Microsurgery - Genova (IT)
Prof. Francesco Boccardo presents our clinical trial, while Lymphatica Medtech will be at the booth 13. Come meet us!
June 15th, 2023
Lymphatica obtains CHF 400’000 of the FIT Growth Loan
The FIT Tech program aims to support entrepreneurs who develop technological projects in the Canton of Vaud and in the Western part of Switzerland, based on a technological innovation that is difficult to imitate and has a high growth potential. It consists in a Loan of up to CHF 400’000, which will be used to accelerate the production, verification, and validation of our product.
April 28th, 2023
Lymphatica obtains the Swiss Accelerator Grant: CHF 2.5 million to accelerate market entry
Lymphatica Medtech has obtained the support of Innosuisse in the frame of the Swiss Accelerator: a grant CHF 2.5 million to finance the LyBRA project: Lymphatic Bypass for Recirculation of Accumulated fluids in leg lymphedema patients. The project aims at accelerating the time to market for the leg version of the LymphoDrain device.
March 29th, 2023
Lymphatica showcasing at the Medtech Innovator Pitching Event in Baltimore - USA
Lymphatica was selected to participate at the Medtech Innovator East Coast Pitching Event in Baltimore, United States. Lymphatica CEO will present the Company in front of a large cohort of investors, clinicians and expert.
March 23rd, 2023
Lymphatica is presenting at the LSI Emerging Medtech summit USA
Lymphatica’s CEO will present the Company, its achievements and its growth plans to a relevant cohort of international investors and industry experts.
December 15th, 2022
LymphoPILOT first-in-human clinical trial is halfway - preliminary results reveals promising results for upper limb lymphedema patients
The study, which includes a 2 months implantation period of our device, is being conducted at the Lausanne University Hospital (link). As of today, the study was completed by 6 upper limb lymphedema patients. While results are still preliminary, they confirm LymphoDrain potential for drastically improving lymphedema patient’s outcome and quality of life.
December 5th, 2022
Lymphatica successfully renews its ISO 13485 certificate from TÜV SÜD
After in depth audit, the notified body TÜV SÜD granted the renewal of the ISO 13485 certification to Lymphatica Medtech SA. ISO 13485 is the international quality management system standard for medical devices, ensuring the highest medical device quality for patient safety. The certificate can be downloaded here.
February 22nd, 2022
Lymphatica is awarded with the Innosuisse Certificate
After more than 3 years of milestone-based support and coaching, the Swiss Innovation Agency conferred to us the Innosuisse Certificate, certifying that Lymphatica is ready for sustainable investment and sustainable growth.
November 23rd, 2021
Lymphatica receives the Top Presenting Companies Award from Tech Tour Health
Lymphatica’s CEO participated to both the live and live events of the Tech Tour Health 2021, and received the Award as Top Presenting Company In recognition for outstanding Pitching performance throughout the Program and high quality presentation as evaluated by a panel of International Investor Reviewers. The winner will be invited to pitch at the annual Tech Tour Event Future22 in March 2022.
More info at this link
September 8th, 2021
Start of the LymphoPILOT first in man clinical trial
After approval by Swissmedics and by the CER-VD Ethical committee, the LymphoPILOT clinical trial officially started.
For a more details about the study please visit clinical trial.gov
July 27th, 2021
Lymphatica is among the Winners of Venture Leaders Medtech 2021
Lymphatica was selected in the Swiss National Startup Team for the Venture Leaders Medtech 2021 roadshow in Boston – USA.
The company CEO, Marco Pisano, was interviewed here.
Venture Leaders Medtech 2021 is organized by Venturelab and supported by EPF Lausanne, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, Paul Scherrer Institut, Swissnex Boston, University Zurich, Canton of Vaud, and Canton of Zurich.
December 3rd, 2020
Lymphatica closes Series A financing round
We are happy to announce that we have closed a 7 digit Series A financing round!
The investment round was led by the High Tech Gründerfonds (https://www.htgf.de/en/) , a large and experienced German VC fund that will accompany on our way forward.
New business angels joined the round, as well as the existing ones, who confirmed the trust in our team.
The EIT Health (https://eithealth.eu/ – European Institute of Technology) contributed to the financement, funding development activities to improve the usability and digitalization of our product, LymphoDRAIN.
Together with the cash, we welcome Laurent Duhoux as new member of our Board of Directors. With a proven track record in managing medical technology businesses, Laurent brings to Lymphatica his 20-year experience.
We’ll use the funds to advance in the roadmap to bring LymphoDRAIN to lymphedema patients.
More details in our press release.
December 11th, 2019
Lymphatica obtains ISO 13485 certificate from TÜV SÜD
Notified body TÜV SÜD granted the ISO 13485 certification to Lymphatica Medtech SA!
ISO 13485 is the international quality management system standard for medical devices.
This certification confirms that Lymphatica operated through highly controlled quality proceses and procedures tailored to optimized the design & development of medical devices.
The certification was awarded following independent audits according to ISO 13485:2016 requirements.
September 1st, 2019
Lymphatica obtains 1.8 million Euro funding from the EU!
The European Innovation Council of the European Union supports LymphoDrain implant market entry with €1.8 millions grant, via its H2020 SME Instrument program. This additional fund will accelerate the market entry process, supporting pre-series manufacturing and clinical trials.
Being awarded in such a highly competitive selection process is a recognition of excellence of the presented product innovation and of the expected large societal impact.
The EIC Accelerator (former SME Instrument) is a public funding program that funds breakthrough innovation in small businesses. Only the most innovative companies get selected: only 83 projects were funded out of 1765 submitted proposals at the April 2019 call.
More info here.
June 24th-July 4th, 2019
Lymphatica is among the Winners of Venture Leaders China 2019
Lymphatica is selected among the 10 Venture Leaders for a fundraising campaign in China
Venture Leaders China 2019
June 13-15, 2019
Lymphatica presents at the International Lymphoedema Framework Conference in Chicago
We will present our latest results at the International Lymphatic Framework Conference in Chicago (13-15 June, 2019). Please come and visit us!
May 8-9, 2019
Lymphatica presents at the 28th Medtech Investing Europe Conference
Lymphatica Medtech was selected between the presenting companies at the 28th Medtech Investing Europe Conference
March 20th, 2019
CHUV, our main clinical partner, is rated as one of "The 10 Best hospitals in the World" (NewsWeek)
February 2nd, 2019
Lymphatica joins the congress "History and Present of Italian Phlebology"
Lymphatica participates to a round table to discuss about the future of lymphedema care
December 10th, 2018
Lymphatica is a finalist at the European Venture Contest
Lymphatica was selected to participate at the 12th edition of the European Venture Contest Final – Europe’s leading network and investment event for high-growth technological start-ups, venture capital investors and technological corporations